🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions

Recruitingn/aAges 18 Years - anyAllIstituto Clinico Humanitas
NCT07401615 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites. Even so, some patients later develop a local recurrence, meaning the cancer comes back in the same area that was previously treated with radiation. When this happens, treatment options are limited. Surgery can sometimes remove the recurrent tumor, but many patients are not able to have surgery because of their general health or because the tumor is difficult to remove. For these patients, a second course of radiotherapy (called re-irradiation) may be the only possible treatment. One type of radiotherapy, called stereotactic body radiotherapy (SBRT), delivers very high doses of radiation very precisely. SBRT has been used successfully as a second treatment after

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Inoperable primary non-small cell lung cancer or other metastatic primaries with lung metastases, already treated with radical dose SBRT * Inoperable local recurrence (defined as a tumor recurrence overlapping the 50% isodose field) confirmed by documented radiographic findings and/or pathological biopsies within the thoracic area * Patients had previously received curative intent SBRT with a biologically equivalent dose equal or higher than 75 Gy * Stereotactic reirradiation with ablative purposes up to 8 fractions * No active distant metastasis or controlled distant metastasis at the time of re-irradiation * More than 12 months from previous SBRT * PS ≤ 2 Exclusion Criteria: * Previous conventional RT * Reirradiation with palliative doses * Reirradiation with conventionally fractionated or mildly hypofractionated RT
💊

What it tests

  • Not listed
📍

Where

11 sites
AST Papa Giovanni XXIII
Bergamo, Italy
Radiotherapy Department, Ospedale Bellaria Carlo Alberto Pizzardi
Bologna, Italy
REM Radioterapia
Catania, Italy
Radiation oncology unit, Ospedale San Raffaele
Milan, Italy
Radiotherapy Department, Istituto Europeo di Oncologia
Milan, Italy
IRCCS Humanitas Research Hospital
Rozzano, Italy
Radiotherapy Department, IRCCS Istituto Nazionale Fondazione G. Pascale
Naples, Italy
Centro Fondazione Policlinico Universitario "A. Gemelli", Radioterapia Oncologica
Roma, Italy

…and 3 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy